NCT05841472 - Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Non Squamous Non Small Cell Lung Cancer

Interventions

DRUG

Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin

"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."

Trial Locations (8)

Unknown

RECRUITING

Korea University Anam Hospital, Anam

RECRUITING

Hallym University Sacred Heart Hospital, Anyang

RECRUITING

Chonnam National University Hwasun Hospital, Hwasun

RECRUITING

Catholic University of Korea EunPyeong St. Mary's Hospital, Seoul

RECRUITING

Catholic University of Korea Yeouido St. Mary's Hospital, Seoul

RECRUITING

Korea University Guro Hospital, Seoul

RECRUITING

Seoul Asan Hospital, Seoul

RECRUITING

Busan National University Hospital Yangsan, Yangsan